Kate Sasser
Chief Scientific Officer Tempus
Seminars
Wednesday 7th October 2026
The New Frontier of Precision Medicine – From Tumor Fingerprint to Dose: Integrating Data & NGS to Power Neoantigen Therapies
9:40 am
- The paradigm of precision oncology is shifting from standard biomarker targeting to highly personalized, data-driven therapies
- In this fireside chat, we will discuss how combining next-generation sequencing (NGS) and advanced therapeutic platforms is accelerating the development of neoantigen therapies and personalized medicines, and has the potential to transform cancer care
